Improving T-cell engager efficacy in glioblastoma with multi-antigen targeting and novel delivery approaches
Acta Neuropathologica · 03.08.2026 · 152 (1)
DOI: 10.1007/s00401-026-03063-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Neuropathologica, online erschienen am 03.08.2026. Verfasst von Arushi Tiwari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of …. Hauptthemen laut MEDLINE: Glioblastoma, T-Lymphocytes, Brain Neoplasms, Immunotherapy. Die Arbeit nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH, the Pat & Shirley Ryan Family Research Accelerator Award.
Abstract (Originalsprache)
Glioblastoma remains a challenging disease to approach with immunotherapy due to pronounced antigen heterogeneity, immunosuppressive tumor microenvironment, and barriers to effective molecule delivery within the central nervous system. T-cell engagers provide an off-the-shelf approach to redirect endogenous T cells toward tumor cells. However, bispecific formats are constrained by intra- and interpatient antigen heterogeneity, which can limit therapeutic efficacy. In this review, we examine trispecific T-cell engagers (TriTEs) as an emerging strategy to address this limitation by simultaneously targeting multiple tumor-associated antigens. We discuss principles guiding antigen selection in glioblastoma, summarize available preclinical evidence supporting multispecific engagement, and outline key design considerations, including molecular architecture, stability, half-life extension, and safety optimization. We further review delivery strategies, such as gene-encoded expression, cellular carriers, and blood–brain barrier modulation, that may improve tumor access and the durability of TriTEs. Together, these considerations position TriTEs as a modular immunotherapy platform relevant to glioblastoma and other heterogeneous solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery, Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 303 E Superior St., Chicago, IL, 60…
- Department of Neurology, University of Michigan, 1500 E Medical Center Dr., Ann Arbor, MI, 48109, USA.
Förderung
- NINDS NIH HHS
- NIH
- the Pat & Shirley Ryan Family Research Accelerator Award
- Chicago Biomedical Consortium Accelerator Award
Zitieren
APA
Tiwari, A., Pawlowski, K. D., & Balyasnikova, I. V. (2026). Improving T-cell engager efficacy in glioblastoma with multi-antigen targeting and novel delivery approaches. Acta Neuropathologica, 152(1). https://doi.org/10.1007/s00401-026-03063-w
Vancouver
Tiwari A, Pawlowski KD, Balyasnikova IV. Improving T-cell engager efficacy in glioblastoma with multi-antigen targeting and novel delivery approaches. Acta Neuropathologica. 2026;152(1). doi:10.1007/s00401-026-03063-w
BibTeX
@article{Tiwari2026,
author = {Tiwari, Arushi and Pawlowski, Kristen D and Balyasnikova, Irina V},
title = {Improving T-cell engager efficacy in glioblastoma with multi-antigen targeting and novel delivery approaches},
journal = {Acta Neuropathologica},
year = {2026},
volume = {152},
number = {1},
doi = {10.1007/s00401-026-03063-w}
}
EUVIMED